Journal of Rheumatic Diseases

Cited by CrossRef (3)

  1. Min Wook So, A-Ran Kim, Seung-Geun Lee. Drug Persistence and Incidence of Active Tuberculosis of Tumor Necrosis Factor Alpha Inhibitors Versus Tocilizumab as the First-Line Biological Treatment in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Retrospective Cohort Analysis. Rheumatol Ther 2024;11:881
    https://doi.org/10.1007/s40744-024-00674-1
  2. A. O. Bobkova, A. M. Lila, A. E. Karateev. Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors. Sovremennaâ revmatologiâ 2024;18:16
    https://doi.org/10.14412/1996-7012-2024-4-16-22
  3. Young Ho Lee, Gwan Gyu Song. The role of NLRP3 and CARD8 polymorphisms in the risk of rheumatoid arthritis: A meta‐analysis of genetic association studies. Int J of Rheum Dis 2023;26:2214
    https://doi.org/10.1111/1756-185X.14917